Skip to main content
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp — Investor Relations & Filings

Ticker · ABUS ISIN · CA03879J1003 US Manufacturing
Open in API
Filings indexed 1,013 across all filing types
Latest filing 2025-04-21 Regulatory Filings
Country US United States of America
Listing US ABUS

About Arbutus Biopharma Corp

https://www.arbutusbio.com/

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases, with a primary emphasis on creating a functional cure for chronic Hepatitis B virus (cHBV) infection. The company's strategy involves developing combination regimens that utilize multiple agents with complementary mechanisms of action. This approach aims to suppress viral replication, reduce viral antigens, and reawaken the host's immune response. A key candidate in its pipeline is imdusiran, an RNA interference (RNAi) therapeutic. Arbutus leverages its expertise in virology and drug delivery systems to advance its portfolio of clinical assets for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-04-21 English
Regulatory Filings 2025
Regulatory Filings
2025-04-15 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' related to a Proxy Statement. Proxy Statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document length is short (1072 characters), consistent with additional proxy materials rather than a full report. Therefore, the correct classification is PSI.
2025-04-04 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-04 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes announcements of termination and post-termination agreements of senior officers (Chief Medical Officer and Chief Financial Officer), which are changes in senior management. It also includes an update on a legal proceeding related to a patent infringement lawsuit. The primary focus is on management changes and related agreements, which fits the category of Board/Management Information (MANG). The document is not a full financial report, earnings release, or other report types. Therefore, the classification is MANG with high confidence.
2025-04-03 English
FORM 4/A
Director's Dealing
2025-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.